Increased fibroblast growth factor-like autoantibodies in serum from a subset of patients with cancer-associated hypercalcemia

Life Sciences

Volumn 71, Issue 25, 2002, Pages 2939-2959

  Zimering, Mark B ^a   Thakker Varia, Smita ^b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Antiidiotype antibodies; Bone metastases; Fibroblast growth factor; Prolactin

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; BASIC FIBROBLAST GROWTH FACTOR; HYDROXYAPATITE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; NEUTRALIZING ANTIBODY; PROTEIN A; SODIUM DIHYDROGEN PHOSPHATE;

ADULT; AGED; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER; CANCER PATIENT; CELL ACTIVITY; CELL ASSAY; CELL PROLIFERATION; CHROMATOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; ELUTION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HYPERCALCEMIA; HYPERPROLACTINEMIA; IMMUNOBLOTTING; KIDNEY CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROSTATE CARCINOMA; RABBIT; SERUM; SPINAL CORD COMPRESSION; SPINAL CORD METASTASIS; STORAGE TEMPERATURE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; AUTOANTIBODIES; BONE NEOPLASMS; CELL DIVISION; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYPERCALCEMIA; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PROLACTIN; RABBITS; TUMOR CELLS, CULTURED;

ORYCTOLAGUS CUNICULUS;

EID: 0037044811     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02160-4     Document Type: Article

References (63)

1. Janjan N. Bone metastases: approaches to management. Seminars in Oncology. 28:2001;35-41.
2. Pfeilschifter J., Mundy G.R. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proceedings of the National Academy of Sciences USA. 84:1987;2024-2028.
3. Gospodarowicz D., Ferrara N., Schweigerer L., Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocrine Reviews. 8:1987;95-114.
4. Bellus G.A., Gaudenz K., Zackai E.H., Clarke L.A., Szabo J., Francomano C.A., Muenke M. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndrome. Nature Genetics. 14:1996;174-176.
5. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., Takeuchi Y., Fugita T., Fukumoto S., Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proceedings of the National Academy of Sciences. 98(11):2001;6500-6505.
6. Gospodarowicz D., Cheng J., Lui G.M., Baird A., Bohlen P. Isolation of brain fibroblast growth factor by heparin-Sepharose affinity chromatography: identity with pituitary fibroblast growth factor. Proceedings of the National Academy of Sciences USA. 81:1984;6963-6967.
7. Gospodarowicz D., Cheng J., Lui G.M., Fujii D.K., Baird A., Bohlen P. Fibroblast growth factor in human placenta. Biochemical Biophysical Research Communications. 128:1985;554-562.
8. Gospodarowicz D., Baird A., Cheng J., Lui G.M., Esch F., Bohlen P. Isolation of fibroblast growth factor from bovine adrenal gland: physiochemical and biological characterization. Endocrinology. 118:1986;82-90.
9. Gospodarowicz D., Cheng J., Lui G.M., Baird A., Esch F., Bohlen P. Corpus luteum angiogenic factor is related to fibroblast growth factor. Endocrinology. 117:1985;2383-2391.
10. Hauschka P.V., Mavrakos A.E., Iafrati M.D., Doleman S.E., Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. Journal of Biological Chemistry. 261:1986;12665-12674.
11. Esch F., Baird A., Ling N., Ueno N., Hill F., Denoroy L., Klepper R., Gospodarowicz D., Bohlen P., Guillemin R. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proceedings of the National Academy of Sciences (USA). 19:1985;6507-6511.
12. Gauthier T., Maftouh M., Picard C. Rapid enzymatic degradation of (125I)(Tyr10) FGF(1-10) by serum in vitro and involvement in the determination of circulating FGF by RIA. Biochemical Biophysical Research Communications. 145:1987;775-781.
13. Zimering M.B., Brandi M.L., DeGrange D.A., Marx S.J., Streeten E., Katsumata N., Murphy P.R., Sato Y., Friesen H.G., Aurbach G.D. Circulating fibroblast growth factor-like substance in familial multiple endocrine neoplasia type 1. Journal of Clinical Endocrinology and Metabolism. 70:1990;149-154.
14. Zimering M.B., Katsumata N., Sato Y., Brandi M.L., Aurbach G.D., Marx S.J., Friesen H.G. Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: relation to pituitary tumor. Journal of Clinical Endocrinology and Metabolism. 76:1993;1182-1187.
15. Kurobe M., Takei Y., Ezawa H., Hayashi K. Increased level of basic fibroblast growth factor (bFGF) in sera of patients with malignant tumors. Hormone Metabolism Research. 25:1993;395-396.
16. Takei Y., Higashira I.H., Yamamoto T., Hayashi K. Mitogenic activity toward human breast cancer cell line MCF-7 of two bFGFs purified from sera of breast cancer patients: co-operative role of cathepsin D. Breast Cancer Research and Treatment. 43:1997;53-63.
17. Zimering M.B., Riley D.J., Thakker-Varia S., Walker A.M., Lakshminaryan V., Shah R., Brandi M.L., Ezzat S., Katsumata N., Friesen H.G., Marx S.J., Eng J. Circulating fibroblast growth factor-like autoantibodies in two patients with multiple endocrine neoplasia type 1 and prolactinoma. Journal of Clinical Endocrinology and Metabolism. 79:1994;1546-1552.
18. Bernton E.W., Metzler M.S., Holaday J.W. Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science. 239:1988;401-404.
19. Warrell R., Mullane M., Bilezikian J., Edelstein M., Mallete L., Stepanavage M., Averbuch S. The Alendronate Hypercalcemia Study Group Treatment of cancer-associated hypercalcemia with alendronate sodium: a randomized double-blind comparison with etidronate. Proceedings of the American Society for Clinical Oncology. 12:1993;438. [#1514].
20. Zimering M.B. Effect of intravenous bisphosphonates on release of basic fibroblast growth factor in serum of patients with cancer-associated hypercalcemia. Life Sciences. 70:2002;1947-1960.
21. Connolly D.T., Knight M.B., Karakas N.K.et al. Determination of the number of endothelial cells in culture using an acid phosphatase assay. Analytical Biochemistry. 152:1986;136-141.
22. Schneider C., Sutherland R., Newman R., Greaves M. Structural features of the cell surface receptor for transferrin that is recognized by the monoclonal antibody OKT9. Journal of Biological Chemistry. 257:1982;8516-8522.
23. Harlow E., Lane D. Antibodies: A Laboratory Manual: Cold Spring Harbor Laboratory. 1988;306-307 Cold Spring Harbor, NY.
24. Fleisch H. Composition of bone. Bisphosphonates in Bone Disease. 2000;3-5 Academic Press, San Diego, California.
25. Hill D.J., Tevaarwerk G.J.M., Arany E., Kilkenny D., Gregory M., Langford K.S., Miell J. Fibroblast growth factor-2 (FGF-2) is present in maternal and cord serum, and in the mother is associated with a binding protein immunologically related to the FGF receptor-1. Journal of Clinical Endocrinology and Metabolism. 80:1995;1822-1831.
26. Wang J.F., Shen M., Fong G.H., Hill D.J. A soluble fibroblast growth factor receptor is released from HL-60 promyelocytic leukemia cells: implications for paracrine growth control. Growth Factors. 17(3):2000;203-214.
27. Adams D.D. Long-acting thyroid-stimulator: how receptor autoimmunity was discovered. Autoimmunity. 1:1988;3-9.
28. Fuchs S. Auto-immune response to AchR in myasthenia gravis. Current Topics in Microbiology and Immunology. 85:1979;23-25.
29. Flier J.S., Kahn C.R., Jarett D.B., Roth J. Characterization of antibodies to the insulin receptor: a cause of insulin-resistant diabetes in man. Journal of Clinical Investigation. 58:1976;1442-1449.
30. Taylor S.I., Grunberger G., Marcus-Samuels B., Underhill L.H., Dons R.F., Ryan J., Roddam R.F., Rupe C.E., Gorden P. Hypoglycemia associated with antibodies to the insulin receptor. New England Journal of Medicine. 307:1982;1422-1426.
31. David C., Solimena M., DeCamilla P. Autoimmunity in stiff-man syndrome with breast cancer is targeted to the C-terminal region of human amphiphysin, a protein similar to the yeast protein Rvs 167 and Rvs 161. Federation of Experimental Biological Sciences Letters. 351(1):1994;73-79.
32. Polans A.S., Witkowska D., Haley T.L., Amundson D., Baizer L., Adamus G. Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proceedings of the National Academy of Sciences (USA). 92(20):1995;9176-9180.
33. Jerne N.K. Towards a network theory of the immune system. Annals of Immunology (Institut Pasteur). 125C:1974;373-389.
34. Sege K., Peterson P.A. Use of anti-idiotypic antibodies as cell surface receptor probes. Proceedings of the National Academy of Sciences (USA). 75:1978;2443-2447.
35. Roitt I.M. Essential Immunology. 1974;Blackwell, Oxford.
36. Gajdusek C.M., Carbon S. Injury-induced release of basic fibroblast growth factor from bovine aortic endothelium. Journal of Cellular Physiology. 139:1989;570-579.
37. Ferrara N., Clapp C., Weiner R. The 16 K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology. 129:1991;896-900.
38. Baird A., Schubert D., Ling N., Guillemin R. Receptor- and heparin-binding domains of basic fibroblast growth factor. Proceedings of the National Academy of Sciences USA. 85:1988;2324-2328.
39. Feige J.J., Baird A. Basic fibroblast growth factor is a substrate for protein phosphorylation and is phosphorylated by capillary endothelial cells in culture. Proceedings of the National Academy of Science USA. 86:1989;3174-3178.
40. Neufeld G., Gospodarowicz D. The identification and partial characterization of the FGF receptor of baby hamster kidney cells. Journal of Biological Chemistry. 260:1985;13860-13868.
41. Izhicka E., Dunstan C., Esparza J., Jacobs C., Sabitini M., Mundy G.R. Human amniotic tumor that induces new bone formation in vivo produces growth regulatory activity in vitro to osteoblasts identified as an extended form of bFGF. Cancer Research. 56(3):1996;633-636.
42. Karey K.P., Sirbasku D.A. A differential responsiveness of human breast cancer cell line MCF-7 and T47D to growth factors and 17b-estradiol. Cancer Research. 48:1988;870-874.
43. Yarden Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proceedings of the National Academy of Sciences USA. 87(7):1990;2569-2573.
44. Clevenger C.V., Russell D.H., Appasamy P.M., Prystowsky M.B. Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proceedings of the National Academy of Sciences (USA). 87(16):1990;6460-6464.
45. Spangelo B., Hall N.R.S., Ross P.C., Goldstein A.L. Stimulation of in vivo antibody production and Concanavalin-A-induced mouse spleen cell mitogenesis by prolactin. Immunopharmacology. 14:1987;11-20.
46. McMurray R., Keisler D., Kanuckel K., Izui S., Walker S.E. Prolactin influences autoimmune disease activity in the female B/W mouse. Journal of Immunology. 147(11):1991;3780-3787.
47. Berry W.R., Laszlo J., Cox E., Walker A., Paulson D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer. 44(2):1979;763-765.
48. Wang D.Y., Stepniewska K.A., Allen D.S., Fentiman I.S., Bulbrook R.D., Kwa H.G., DeStavola B.L., Reed M.J. Serum prolactin levels and their relationship to survival in women with operable breast cancer. Journal of Clinical Epidemiology. 48(7):1995;959-968.
49. Garcia K.C., Ronco P.M., Verroust P.J., Brunger A.T., Amzel L.M. Three-dimensional structure of an angiotensin II-Fab complex at 3A: hormone recognition by an anti-idiotypic antibody. Science. 257:1992;502-507.
50. Kolesnikov A.V., Kozyr A.V., Alexandrova E.S., Koralewski F., Demin A.V., Titov M.I., Avalle B., Tramontano A., Paul S., Thomas D., Gabibov A.G., Friboulet A. Enzyme mimicry by the anti-idiotypic antibody approach. Proceedings of the National Academy of Sciences (USA). 97(25):2000;13526-13531.
51. Fuks Z., Persaud R.S., Alfieri A., McLoughlin M., Ehleiter D., Schwartz J.L., Seddon A.P., Cordon-Cardo C., Haimovitz-Friedman A. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Research. 54(10):1994;2582-2590.
52. Holtkamp W., Osterloh B., Raushcecker H., Nagel G.A. Mastectomy stimulates prolactin release in breast cancer patients. Anticancer Research. 6(4):1986;725-727.
53. Folkman J., Klagsbrun M. Angiogenic factors. Science. 235:1987;442-447.
54. Hurley M.M., Tetradis S., Huang Y.F., Hock J., Kream B.E., Raisz L.G., Sabbieti M.G. Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. Journal of Bone & Mineral Research. 14:1999;776-783.
55. Colomer R., Aparicio J., Montero S., Guzman C., Larrodera L., Cortes-Funes H. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. British Journal of Cancer. 76:1997;1215-1220.
56. Korah R.M., Sysounthone V., Golowa Y., Wieder R. Basic fibroblast growth factor confers a less malignant phenotype in MDA-MB-231 human breast cancer cells. Cancer Research. 60:2000;733-740.
57. Guilbert B., Dighiero G., Avrameas S. Naturally-occurring antibodies against nine common antigens in normal humans. I. Detection, isolation, and characterization. Journal of Immunology. 128:1982;2779-2787.
58. Ramsey-Goldman R., Mattai S.A., Schilling E., Chiu Y.L., Alo C.J., Howe H.L., Manzi S. Increased risk of malignancy in patients with systemic lupus erythematosus. Journal of Investigative Medicine. 46(5):1998;217-222.
59. Giani C., Fierabracci P., Bonacci R., Gigliotti A., Campani D., De Negri F., Cecchetti D., Martino E., Pinchera A. Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. Journal of Clinical Endocrinology and Metabolism. 3:1996;990-994.
60. Gilead Z., Hatzubai A., Sulitzeanu D. Antigens in immune complexes from patients with breast cancer. Cancer Immunology Immunotherapy. 13:1982;153-157.
61. Gordon B.R., Moroff S., Hurvitz A.I., Matus R.E., MacEwen E.G., Good R.A., Day N.K. Circulating immune complexes in sera of dogs with benign and malignant breast disease. Cancer Research. 40(10):1980;3627-3631.
62. Thurfjell E., Thurfjell M.G., Lindgren A. Mammographic findings as predictor of survival in 1-9 mm invasive breast cancer. Worse prognosis for cases presenting as calcification alone. Breast Cancer Research Treatment. 67(2):2001;177-180.
63. Kiel D.P., Kauppila L.I., Cupples L.A., Hannan M.T., O'Donnell C.J., Wilson P.W. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcified Tissue International. 68(5):2001;271-276.